Michael G Douvas1, Lara L Riegler2. 1. University of Virginia Health System, 6011 West Complex, University of Virginia Hospital, Charlottesville, VA, 22908-0716, USA. mgd9a@virginia.edu. 2. University of Virginia Health System, Charlottesville, VA, USA.
Abstract
PURPOSE OF REVIEW: To discuss the long-term view of treating and following pediatric, adolescent, and young adult patients with acute lymphoblastic leukemia (ALL) - with review of what can be done to prevent, monitor for, and treat complications of therapy. RECENT FINDINGS: Pediatric, adolescent, and young adult oncology patients, including those with ALL, are living longer with higher overall survival rates as treatments and supportive care for these patients continue to improve. These patients are burdened by the risk of significant health and quality of life consequences as a result of their treatment.. For these patients, the late effects of treatment can be life-threatening, such as secondary cancers or cardiotoxicity, or life-altering with respect to quality of life. The goal of this paper is to review the current literature, research, and surveillance guidelines regarding the late effects of ALL therapy, to outline what can be done to mitigate the toxic effects of oncology treatment, and to extend life expectancy and improve quality of life for our patients. We review risk factors and interventions available to prevent and treat cardiovascular disease, secondary malignancies, endocrine complications (obesity, osteoporosis, infertility, and premature menopause), cognitive effects, and effects on functioning and mortality.
PURPOSE OF REVIEW: To discuss the long-term view of treating and following pediatric, adolescent, and young adult patients with acute lymphoblastic leukemia (ALL) - with review of what can be done to prevent, monitor for, and treat complications of therapy. RECENT FINDINGS: Pediatric, adolescent, and young adult oncology patients, including those with ALL, are living longer with higher overall survival rates as treatments and supportive care for these patients continue to improve. These patients are burdened by the risk of significant health and quality of life consequences as a result of their treatment.. For these patients, the late effects of treatment can be life-threatening, such as secondary cancers or cardiotoxicity, or life-altering with respect to quality of life. The goal of this paper is to review the current literature, research, and surveillance guidelines regarding the late effects of ALL therapy, to outline what can be done to mitigate the toxic effects of oncology treatment, and to extend life expectancy and improve quality of life for our patients. We review risk factors and interventions available to prevent and treat cardiovascular disease, secondary malignancies, endocrine complications (obesity, osteoporosis, infertility, and premature menopause), cognitive effects, and effects on functioning and mortality.
Authors: Lillian R Meacham; Charles A Sklar; Suwen Li; Qi Liu; Nora Gimpel; Yutaka Yasui; John A Whitton; Marilyn Stovall; Leslie L Robison; Kevin C Oeffinger Journal: Arch Intern Med Date: 2009-08-10
Authors: Gregory T Armstrong; Kevin C Oeffinger; Yan Chen; Toana Kawashima; Yutaka Yasui; Wendy Leisenring; Marilyn Stovall; Eric J Chow; Charles A Sklar; Daniel A Mulrooney; Ann C Mertens; William Border; Jean-Bernard Durand; Leslie L Robison; Lillian R Meacham Journal: J Clin Oncol Date: 2013-09-03 Impact factor: 44.544
Authors: Stephanie B Dixon; Yan Chen; Yutaka Yasui; Ching-Hon Pui; Stephen P Hunger; Lewis B Silverman; Kirsten K Ness; Daniel M Green; Rebecca M Howell; Wendy M Leisenring; Nina S Kadan-Lottick; Kevin R Krull; Kevin C Oeffinger; Joseph P Neglia; Ann C Mertens; Melissa M Hudson; Leslie L Robison; Gregory T Armstrong; Paul C Nathan Journal: J Clin Oncol Date: 2020-07-24 Impact factor: 44.544
Authors: Renée L Mulder; Anna Font-Gonzalez; Eline van Dulmen-den Broeder; Gwendolyn P Quinn; Jill P Ginsberg; Erik A H Loeffen; Melissa M Hudson; Karen C Burns; Hanneke M van Santen; Claire Berger; Tamara Diesch; Uta Dirksen; Aleksander Giwercman; Clarisa Gracia; Sarah E Hunter; Joanne F Kelvin; James L Klosky; Joop S E Laven; Barbara A Lockart; Sebastian J C M M Neggers; Michelle Peate; Bob Phillips; Damon R Reed; Eva Maria E Tinner; Julianne Byrne; Margreet Veening; Marleen van de Berg; Chris M Verhaak; Antoinette Anazodo; Kenny Rodriguez-Wallberg; Marry M van den Heuvel-Eibrink; Ogechukwu A Asogwa; Alexandra Brownsdon; W Hamish Wallace; Daniel M Green; Roderick Skinner; Riccardo Haupt; Lisa B Kenney; Jennifer Levine; Marianne D van de Wetering; Wim J E Tissing; Norbert W Paul; Leontien C M Kremer; Julia Inthorn Journal: Lancet Oncol Date: 2021-02 Impact factor: 41.316
Authors: Barbara L Asselin; Meenakshi Devidas; Lu Chen; Vivian I Franco; Jeanette Pullen; Michael J Borowitz; Robert E Hutchison; Yaddanapudi Ravindranath; Saro H Armenian; Bruce M Camitta; Steven E Lipshultz Journal: J Clin Oncol Date: 2015-12-23 Impact factor: 44.544
Authors: Kevin C Oeffinger; Ann C Mertens; Charles A Sklar; Toana Kawashima; Melissa M Hudson; Anna T Meadows; Debra L Friedman; Neyssa Marina; Wendy Hobbie; Nina S Kadan-Lottick; Cindy L Schwartz; Wendy Leisenring; Leslie L Robison Journal: N Engl J Med Date: 2006-10-12 Impact factor: 176.079